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[57] ABSTRACT. 
Apparatus and methods for noninvasively diagnosing 
diabetes mellitus, the prediabetic condition, and cata-
racts in the human (or other) body are disclosed. Diag-
noses are made by illuminating ocular lens tissue-with a 
narrow-band light source at a selected wavelength, 
detecting the backscattered radiation intensity at the 
peak of the fluorescent response, and normalizing the 
detected value with the intensity of its Rayleigh compo-
nent. Measurements provided in this manner can be 
used as improved indicators of the presence or absence 
of certain diseases or conditions. 
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APPARATUS AND METHODS FOR 
QUANTITATIVELY MEASURING MOLECULAR 
CHANGES IN THE OCULAR LENS 
Because lenses typically cloud naturally as patients 
age, however, measurements made in connection with 
the methods of the Weiss patents can be taken only from 
clear sites in the patients' lenses. The Weiss techniques 
This invention relates to evaluating changes in bio-
logical tissues and more specifically to apparatus and 
methods for quantitatively measuring molecular 
changes in the lens of the eye. 
s also appear unable to distinguish the ultimate cause of 
changes in diffusion coefficients or to detect the predia-
betic condition (i.e. where no overt clinical signs of 
diabetes are displayed but will be exhibited within ap-
proximately five years as, for example, when a positive 
BACKGROUND OF THE INVENTION 
10 ICA test occurs), since myriad diseases and physiolog-
ical conditions are known to affect the lens in the man-
ner therein described. Use of the diffusion coefficient as 
a stand-alone diagnostic test also suffers from its vari-
Existing methods for diagnosing diseases, particu-
larly diabetes, are often less than desirable. One such 
method, the oral glucose tolerance test, attempts to 
assist diagnosis of diabetes mellitus by determining IS 
whether elevated blood glucose levels exist in patients 
suspected of having the disease. Because many patients 
having elevated levels fail subsequently to develop the 
clinical symptoms of the disease, however, the reliabil-
ity of the test is generally questioned. 20 
A second diagnostic method, the Islet Cell Antibody 
(ICA) test, may be used to predict those patients at risk 
for type I diabetes and can predate the onset of debilitat-
ing clinical symptoms by as much as five years. The 
ICA test is not typically utilized, however, because of 2s 
its complexity, expense, and lack of specificity and be-
cause of a lack of standardization among ·evaluating 
laboratories. Furthermore, the test is useful only for 
detecting type I diabetes, which strikes only approxi- 30 
mately ten percent of the entire diabetic patient popula-
tion. By contrast, patients suspected of having the pre-
diabetic condition for type II diabetes currently have no 
confirming diagnostic procedure. 
It is well known that certain portions of the eye fluo- 35 
resce when illuminated. The lens of the eye, for exam-
ple, can be made to fluoresce intensely when illumi-
nated with radiation having a wavelength between ap-
proximately 350 nm and 550 nm. Utilizing radiation of a 
wavelength less than approximately 400 nm typically is 40 
avoided (unless power levels and exposure times are 
restricted), however, since this higher frequency radia-
tion is known to cause damage to ocular tissue. 
The presence of certain diseases in the human body 
cause chemical changes in the lens of the eye, altering 4S 
the amount of the fluorescent response to an illumina-
tion of the lens. The lenses of cataract patients, for 
example, become opaque due to lipid peroxidation, 
protein glycosylation, and the conversion of sulfhydryl 
(-SH) bonds to disulfide bonds (-SS). Similarly, in so 
diabetes mellitus and galactosemia, the glucose and 
galactose are converted to sorbitol and dulcitol, respec-
tively. Accumulation of these compounds results in· a 
high osmotic gradient within the lenticular cells. Pro-
longed therapy with drugs such as corticosteroids and ss 
chlorpromazine also causes opacities of the human lens. 
U.S. Pat. Nos. 4,895,159 and 4,883,351 to Weiss 
(which patents are incorporated herein in their entire-
ties by this reference), thus, disclose methods for detect-
ing the existence of diabetes using light scattered from 60 
lenticular cells. As described in the Weiss patents, the 
backscattered light from a patient suspected of having 
diabetes is used to calculate a diffusion coefficient for 
that patient. A second determination of diffusion coeffi-
cients is made for a control group of nondiabetic pa- 6S 
tients, and the diffusion coefficient of the suspected 
diabetic is compared with those of nondiabetic, control 
group patients of the same age. 
ability as a function of patient age, particularly since 
results have both age-dependent and age-independent 
variance. 
Other patents, such as West German Patent No. 
261957Al to Schiller and U.S. Pat. No. 4,852,987 to 
Lohmann (each of which is incorporated herein in its 
entirety by this reference), describe alternate diagnostic 
methods in which the fluorescence signal intensities are 
compared. The Schiller patent, for example, discloses 
comparing fluorescence signal intensities at two wave-
lengths using a single excitation wavelength in an effort 
to detect the presence of cataracts. The ratio of the 
resulting fluorescence intensities is compared to the 
ratio obtained at the same wavelengths from known 
cataract patients to achieve the desired diagnostic re-
sult. As ciescribed in the Schiller patent, the excitation 
wavelengths are selected from the ranges 320-340 nm, 
380-390 nm, and 430-450 nm, while the intensity of 
fluorescence peaks is measured within wavelength 
ranges of 410-440 nm, 450-460 nm, and 500-520 nm. In 
contrast to the Schiller patent, the Lohmann patent 
measures the magnitude of fluorescence intensity at a 
single wavelength created by light of one excitation 
wavelength and compares this intensity to known inten-
sities at the given wavelengths in order to determine the 
degree of eye lens cloudiness. Neither of these patents, 
however, teaches or suggests detection of diabetes or 
the prediabetic condition. 
SUMMARY OF THE INVENTION 
The present invention provides apparatus and meth-
ods for noninvasively diagnosing selected diseases,.in-
cluding diabetes and the prediabetic condition, in tissues 
of humans or other animals. Utilizing a narrow-band 
light source of wavelength between 400-430 nm (and, 
preferably, approximately 406.7 nm) from a laser or 
similar device and a confocal lens system, the present 
invention illuminates the ocular lens tissue and deter-
mines the intensity of the backscattered radiation at 
both the peak of the fluorescent response (typically at 
approximately 490 nm within the range 460-500 nm) 
and the peak of the Rayleigh component (at the excita-
tion wavelength). The detected radiation subsequently 
is transmitted to a spectrometer to be divided into its 
various components (e.g. fluorescence and Rayleigh). 
The intensity of the fluorescent component is then nor-
malized to the intensity of the Rayleigh component by 
forming the ratio of the fluorescent intensity to the 
Rayleigh intensity. The relative amounts of the back-
scattered fluorescent and Rayleigh radiation provide a 
reliable indicator of the onset and progression of dis-
eases such as diabetes mellitus, the prediabetic condi-
tion, ancf cataracts in the human or other body. 
Unlike existing techniques such as those described 
above, the present invention essentially eliminates the 
3 
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age-dependent measurement vanat1ons previously 
shown to be present. By measuring the Rayleigh com-
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DETAILED DESCRIPTION 
ponent of the backscattered radiation and using it for FIG. 1 illustrates an optical system S of the present 
normalization, the precise amount of illumination en- invention. Optical system 5 includes a light source lS, 
ergy delivered to the subject lens tissue area relative to S lens 25, a confocal lens system 35, collector 45, and a 
the amount of fluorescence signal generated by the spectrometer SS. Source lS, which provides narrow-
tissue can be determined. This approach reduces com- band illumination, typically may be a low power kryp-
plications associated with variances in lens opacity ton laser tuned to produce radiation having a wave-
which can alter, in an unknown fashion, the level of length between approximately 40()430 nm. In one em-
illumination delivered to the subject area. By diminish- 10 bodiment of optical system S, source lS provides radia-
ing the effect of the subjects' ages on the test results, the tion at a wavelength of 406.7 nm. Also shown in FIG. 1 
technique permits establishment of a clear threshol- are ocular lens tissue L, attenuator 6S, eyepiece 7S, 
d-independent of age-separating the diabetic and detection and processing assembly 8S, an fiber optic 
prediabetic patients from those without the disease. The waveguides 95 and lOS. 
15 According to FIG. 1, attenuator 6S, used to reduce 
invention also neither requires use of a coherent light the power level of the transmitted radiation, receives 
source nor suffers from the Jack of specificity (existing radiation from source lS and forwards it to Jens 2S. 
in, e.g., the Weiss techniques) in discriminating the Lens 2s, which may be a 40X microscope objective or 
ultimate cause of the effect being measured. other similar device, then focuses the (attenuated) radia-
It is therefore an object of the present invention to 20 tion onto the end of waveguide 9S, which in turn trans-
provide apparatus and methods for noninvasively diag- mits the radiation to confocal Jens system 3S. Lens sys-
nosing diabetes mellitus, the prediabetic condition, cata- tem 3S subsequently delivers the radiation to a selected 
racts, and the presence of other disea5es. volume of ocular Jens tissue L (typically approximately 
It is another object of the present invention to pro- 200 cubic micrometers). A modified slit lamp base may 
vide apparatus and methods permitting normalization of 2S be used to house and position Jens system 3S for easy 
a fluorescence signal scattered from a subject eye by the access to Jens tissue L, while lens system 3S itself is 
Rayleigh component of the scattered radiation. designed to permit the same volume of Jens tissue L to 
It is a further object of the present invention to pro- be held in the focal point of collector 4S. In an embodi-
vide apparatus and methods essentially eliminating the ment of the present invention consistent with FIG. 1, 
age-dependent measurement variations previously 30 the aperture US of lens system 3S at its focus is greater 
shown to be present in existing diagnostic techniques. than approximately fifteen micrometers, ensuring that 
It is yet another object of the present invention to the excitation radiation diverges rapidly after passing 
provide apparatus and methods for monitoring the lens through the focal point of lens system 3S and thereby 
tissue over time for, e.g., evaluating the efficacy of reducing the spot intensity of the radiation should it 
diabetes mellitus treatment or preventative techniques 3S encounter any other portions of the ocular tissue. 
dealing with the prediabetic condition. Collector 4 receives the radiation backscattered from 
Other objects, features, and advantages of the present lens tissue Las a result of it being illuminated by radia-
invention will become apparent with reference to the tion from source lS. From collector 4S, the backscat-
remainder of the written portion and the drawings of tered radiation is directed into waveguide lOS and trans-
this application. 40 mitted to the entrance slit 12S of the monochromator 
13S forming spectrometer SS. If desired, collector 45 
also may direct a portion of the backscattered radiation 
to eyepiece 7S, permitting an operator to view the exact 
location of the selected volume of Jens tissue L. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic representation of an apparatus 
of the present invention. 
FIG. 2 is a schematic representation of an alternate 4s 
embodiment of the apparatus of FIG. 1. 
FIG. 3 is a graphical representation of the fluorescent 
signal intensity as a function of age of both diabetic and 
nondiabetic patients obtained using the apparatus of so 
FIG. 1 as described in the EXAMPLE herein. 
FIG. 4 is a graphical representation of the ratio of the 
fluorescent to Rayleigh signal intensities as a function of 
age of both diabetic and nondiabetic patients obtained 
using the apparatus of FIG. 1 as described in the EX- SS 
AMPLE herein. 
FIG.Sis a graphical representation of the fluorescent 
signal intensity as a function of age of both diabetic and 
nondiabetic patients obtained using the apparatus of 
FIG. I for an illumination radiation wavelength outside 60 
the range of that used in connection with the present 
invention. 
FIG. 6 is a graphical representation of the ratio of the 
fluorescent to Rayleigh signal intensities as a function of 
age of both diabetic and nondiabetic patients obtained 65 
using the apparatus of FIG. 1 for an illumination radia-
tion wavelength outside the range of that used in con-
nection with the present invention. 
Division and processing of the backscattered radia-
tion occurs in spectrometer SS and detection and pro-
cessing assembly 8S. Radiation transmitted to spectrom-
eter SS initially is separated into its Rayleigh and flores-
cence components. The two components subsequently 
are directed, respectively and as necessary, to amplifiers 
forming part of assembly 8S, for determination of the 
intensities of each. Assembly 8S also may include a 
digital computer or similar computing device for form-
ing the ratio of the fluorescent and Rayleigh compo-
nents of the backscattered radiation, thereby normaliz-
ing the peak intensity of the fluorescent component. 
An alternate embodiment 10 of optical system S is 
illustrated in FIG. 2. According to FIG. 2, light source 
20, which may be a laser diode, produces radiation of 
wavelength approximately 813.4 nm (within the range 
of approximately 800-860 nm) and is coupled to a non-
linear frequency doubling device 30 to produce the 
desired wavelength output of 406.7 nm (within the 
range 40()430 nm). Light source 20 alternatively may 
be a laser, light emitting diode, or other narrow-band 
light source (including broadband sources coupled to 
optical filters). The radiation subsequently is directed 
through an optical delivery system 40 into the eye 50 of 
. --. 
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a patient. As with the optical system S of FIG. 1, alter-
nate embodiment 10 includes an optical collector 60 
confocal to the delivery system 40 to collect the back-
scattered radiation from the lens of eye SO. Similarly as 
noted above, the backscattered radiation collected in- s 
eludes both a fluorescence signal (typically approxi-
mately 490-500 nm within the range 460-500 nm, or 
within the range 520-600 nm) and an intense Rayleigh 
component at the illumination wavelength. 
FIG. 2 additionally discloses means for separating the 10 
components of interest of the backscattered radiation, 
including dichroic beam splitters 70 and 90, and for 
detecting the intensity of the components simulta-
neously using single chip silicon detectors 100 and 120 
or similar devices. Alternatively, component separation 15 
may be accomplished using beam splitters in conjunc-
tion with optical bandpass filters or dispersive elements 
such as diffraction gratings. Hybrid detector/filter as-
semblies also may be used. Electronic circuitry 130, 
such as but neither limited to nor necessarily requiring 20 
analog amplifiers, analog to digital (AID) converters, 
and a digital computer, processes the data detected by 
detectors 100 and 120, calculates the normalized fluore-
scent/Rayleigh component ratio, and, if desired, makes 
the result available to an operator through a digital 2S 
display or other suitable means. Eyepiece 80, finally, 
may be used by the operator to view the location of the 
excitation focal point in eye SO. 
The present invention may further be understood 
with reference to the following non-limiting EXAM- 30 
PLE. 
EXAMPLE 
FIGS. 3-6 illustrate data obtained from clinical trials 
conducted using sixty-nine (69) human patients aged 3S 
twelve (12) to sixty-five (65). Forty-eight (48) of the 
patients had previously been diagnosed as having diabe-
tes, while the remaining twenty-one (21) had not. FIGS. 
3 shows the total fluorescence signal obtained for each 
patient (expressed in "CountsX 105," where the number 40 
of Counts is a function of the number of emitted pho-
tons per unit time) using an illumination wavelength of 
406.7 nm. FIG. 4 details the results when those same 
fluorescence signals ar normalized by the Rayleigh 
component of the backscattered radiation in accordance 4S 
with the present invention. As illustrated in FIG. 4, 
although the normalized signals trend upward as a func-
tion of age, they evidence clear distinctions between 
those patients known to have diabetes or the prediabetic 
condition and those who did not. The normalized sig- SO 
nals for the nondiabetics, for example, were less than 
thirteen (13), while those for diabetics exceeded fifteen 
(15). 
By contrast, use of an illumination wavelength of 
441.6 nm (outside the range of the present invention) SS 
produced much less desirable results. FIGS. S-6, which 
correspond, respectively, to FIGS. 3-4, show (in FIG. 
6) much less of a distinction between the normalized 
signals for the diabetic as opposed to nondiabetic pa-
tients. Furthermore, those patients who tested ICA 60 
positive are shown to have fluorescent/Rayleigh ratios 
within the range of nondiabetic patient values. As a 
result, no clearly established threshold is available for 
diagnostic purposes. 
The foregoing is provided for purposes of illustration, 65 
explanation, and description of embodiments of the 
present invention. Modifications and adaptations to 
these embodiments will be apparent to those of ordinary 
skill in the art and may be made without departing from 
the scope or spirit of the invention. 
We claim: · 
1. An apparatus for measuring molecular changes in a 
patient having an ocular lens that, when illuminated, is 
capable of backscattering radiation including fluores-
cent and Rayleigh components of determinable intensi-
ties, comprising: 
a. means for illuminating the ocular lens with light 
having a wavelength between approximately 
400-430 nm, thereby causing the ocular lens to 
backscatter radiation in response to the illumina-
tion; 
b. means, responsive to the backscattered radiation, 
for collecting the backscattered radiation; 
c. means, connected to the collecting means, for sepa-
rating the backscattered radiation into its fluores-
cent and Rayleigh components; and 
d. means, connected to the separating means, for (i) 
detecting the intensity of each of the separated 
fluorescent and Rayleigh components and (ii) 
forming the ratio of the detected intensities, 
thereby producing a measurement of molecular 
changes in the ocular lens. 
2. An apparatus according to claim 1 in which the 
illuminating means comprises: 
a. a light source selected from the group consisting of 
lasers, laser diodes coupled to nonlinear frequencY. 
doubling devices, light emitting diodes, and broad-
band sources coupled to optical filters; 
b. a lens, optically responsive to the light from the 
light source, for focusing the light; and 
c. a lens system, optically responsive to the focused 
light, having a focus, and defining an aperture at its 
focus greater than approximately fifteen microme-
ters. · 
3. An apparatus according to claim 2 further compris-
ing an eyepiece means, responsive to the backscattered 
radiation, for permitting an operator to view the ocular 
lens. 
4. An apparatus according to claim 3 in which the 
separating means comprises at least one dichroic beam 
splitter. 
S. An apparatus according to claim 4 in which the 
detecting and forming means comprises at least one 
single chip silicon detector and the wavelength of the 
fluorescent component of the backscattered radiation is 
selected from the group consisting of between approxi-
mately 460-500 nm and 520-600 nm. 
6. An apparatus according to claim S in which the 
detecting and forming means further comprises an am-
plifier. 
7. An apparatus according to claim 6 in which the 
illuminating means further comprises means for adjust-
ing the power level of the illuminating light. 
8. An apparatus for measuring molecular changes in a 
patient having an ocular lens having a volume that, 
when illuminated, is capable of backscattering radiation 
including fluorescent and Rayleigh components of de-
terminable intensities, comprising: 
a. a laser for providing light having a selected wave-
length and power level; 
b. means, optically responsive to the provided light, 
for adjusting the power level of the light; 
c. a lens, optically connected to the adjusting means, 
for focussing the light; 
d. a first optical fiber, optically connected to the lens, 
for receiving the focused light; 
7 
5,203,328 
8 
e. a Jens system, optically connected to the first opti-
cal fiber and defining an aperture having a focus 
greater than approximately fifteen micrometers, 
for delivering the focused light to a selected ap-
proximately two hundred micrometers of the vol- 5 
ume of the ocular lens, thereby causing the ocular 
Jens to backscatter radiation in response to the 
delivered light; 
f. a collector (i) having a focal point encompassing 
the selected volume of the ocular lens to which the 10 
focused light is delivered and (ii) responsive to the 
backscattered radiation, for collecting the back-
scattered radiation; 
g. a second optical fiber, optically connected to the 
collector, for receiving the collected radiation; 15 
h. means, connected to the connecting means, for 
separating the backscattered radiation into its fluo-
rescent and Rayleigh components; and 
i. means, connected to the separating means, for (i) 
detecting the intensity of each of the separated 20 
fluorescent and Rayleigh components and (ii) 
forming the ratio of the detected intensities, 
thereby producing a measurement of molecular 
changes in the optical lens. 
9. An apparatus according to claim 8 in which the 25 
wavelength is approximately 406.7 nm, the separating 
means is a spectrometer, and the detecting and forming 
means comprises a computer. 
10. An apparatus according to claim 9 further com-
prising an eyepiece means responsive to the backseat- 30 
tered radiation, for permitting an operator to view the 
selected volume of the ocular lens, and in which the 
measured molecular changes assist in diagnosing condi-
tions selected from the group consisting of diabetes, the 
prediabetic condition, and cataracts. 35 
11. An apparatus according to claim 8 in which the 
separating means comprises at least one dichroic beam 
splitter. 
12. An apparatus according to claim 11 further com-
prising an eyepiece means responsive to the backseat- 40 
tered radiation, for permitting an operator to view the 
selected volume of the ocular Jens, and in which the 
measured molecular changes assist in diagnosing condi-
tions selected from the group consisting of diabetes, the 
prediabetic condition, and cataracts. 45 
13. A method for measuring molecular changes in a 
patient having tissue that, when illuminated, is capable 
50 
55 
60 
65 
of backscattering radiation including fluorescent and 
Rayleigh components of determinable intensities, com-
prising the steps of: 
a. illuminating the tissue with light having a wave-
length selected from the group consisting of be-
tween approximately 400-430 nm and between 
approximately 800-860, thereby causing the tissue 
to backscatter radiation in response to the illumina-
tion; 
b. separating the backscattered radiation into its fluo-
rescent and Rayleigh components; 
c. detecting the intensity of each of the separated 
fluorescent and Rayleigh components; and 
d. forming the ratio of the detected intensities. 
14. A method according to claim 13 in which the 
illuminating step comprises the steps of: 
a. providing a light source selected from the group 
consisting of lasers, laser diodes coupled to nonlin-
ear frequency doubling devices, light emitting di-
odes, and broadband sources coupled to optical 
filters, for emitting the light at a wavelength of 
approximately 406.7 nm; and 
b. focusing the light using a lens system having a 
focus and defining an aperture at its focus greater 
than approximately fifteen micrometers; and fur-
ther comprising the step of comparing the ratio of 
the detected intensities against at east one prese-
lected value for assisting in diagnosing conditions 
selected from the group consisting of diabetes and 
the prediabetic condition. 
15. A method according to claim 14 in which the 
detecting step comprises the step of detecting the sepa-
rated fluorescent component at a wavelength selected 
from the group consisting of between approximately 
460-500 nm and 520-600 nm and in which the compar-
ing step comprises the step of comparing the ratio of the 
detected intensities against two preselected values, thir-
teen and fifteen, so that if the ratio is Jess than thirteen 
the patient may be diagnosed as unlikely to have the 
selected condition and if the ratio is greater than fifteen 
the patient may be diagnosed as likely to have the se-
lected condition. 
16. A method according to claim 15 in which the 
separating step comprises the step of separating the 
backscattered radiation using at least one dichroic beam 
splitter. 
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